[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL176934A - Use of form v of r-(-)-modafinil in the preparation of a medicament for treating excessive daytime sleepiness and attention deficit hyperactivity disorder (adhd) - Google Patents

Use of form v of r-(-)-modafinil in the preparation of a medicament for treating excessive daytime sleepiness and attention deficit hyperactivity disorder (adhd)

Info

Publication number
IL176934A
IL176934A IL176934A IL17693406A IL176934A IL 176934 A IL176934 A IL 176934A IL 176934 A IL176934 A IL 176934A IL 17693406 A IL17693406 A IL 17693406A IL 176934 A IL176934 A IL 176934A
Authority
IL
Israel
Prior art keywords
modafinil
adhd
medicament
preparation
attention deficit
Prior art date
Application number
IL176934A
Other languages
Hebrew (he)
Other versions
IL176934A0 (en
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/029013 external-priority patent/WO2005023198A2/en
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of IL176934A0 publication Critical patent/IL176934A0/en
Publication of IL176934A publication Critical patent/IL176934A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL176934A 2004-02-06 2006-07-18 Use of form v of r-(-)-modafinil in the preparation of a medicament for treating excessive daytime sleepiness and attention deficit hyperactivity disorder (adhd) IL176934A (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US54275204P 2004-02-06 2004-02-06
US56041104P 2004-04-06 2004-04-06
US57341204P 2004-05-21 2004-05-21
US57917604P 2004-06-12 2004-06-12
US58199204P 2004-06-22 2004-06-22
US58675204P 2004-07-09 2004-07-09
US58823604P 2004-07-15 2004-07-15
PCT/US2004/029013 WO2005023198A2 (en) 2003-09-04 2004-09-04 Modafinil compositions
US63178604P 2004-11-30 2004-11-30
PCT/US2005/002782 WO2005077894A1 (en) 2004-02-06 2005-02-01 Modafinil compositions

Publications (2)

Publication Number Publication Date
IL176934A0 IL176934A0 (en) 2006-12-10
IL176934A true IL176934A (en) 2013-06-27

Family

ID=38456572

Family Applications (1)

Application Number Title Priority Date Filing Date
IL176934A IL176934A (en) 2004-02-06 2006-07-18 Use of form v of r-(-)-modafinil in the preparation of a medicament for treating excessive daytime sleepiness and attention deficit hyperactivity disorder (adhd)

Country Status (7)

Country Link
EP (1) EP1718607A4 (en)
JP (1) JP4917441B2 (en)
AU (1) AU2005212229B2 (en)
CA (1) CA2556106A1 (en)
EA (1) EA009949B1 (en)
IL (1) IL176934A (en)
WO (1) WO2005077894A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1515703A1 (en) 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
FR2849029B1 (en) 2002-12-20 2005-03-18 Lafon Labor PROCESS FOR THE PREPARATION AND CRYSTALLINE FORMS OF OPTICAL ENANTIOMERS OF MODAFINIL.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
CN100343228C (en) * 2006-02-17 2007-10-17 中国科学院上海有机化学研究所 Selective prepn process of single antimer of 2-dibenzylsulfenyl-acetamide with higher antimer
MX2007012605A (en) * 2006-02-21 2008-01-11 Teva Pharma Novel crystalline forms of armodafinil and preparation thereof.
US20100234468A1 (en) * 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
US7960586B2 (en) 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
WO2009045488A2 (en) * 2007-10-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
KR102126389B1 (en) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 A composition for preventing or treating liver diseases comprising benzhydrylthio acetamide derivative as an active ingredient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (en) * 1986-01-31 1988-07-22 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR PREPARATION AND THERAPEUTIC USE
FR2804322B1 (en) * 2000-01-31 2002-04-19 Lafon Labor USE OF MODAFINIL FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR CORRECTING VIGILANCE DISORDERS ASSOCIATED WITH MYOPATHIES
CA2634702C (en) * 2000-07-27 2011-07-19 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same
FR2849029B1 (en) * 2002-12-20 2005-03-18 Lafon Labor PROCESS FOR THE PREPARATION AND CRYSTALLINE FORMS OF OPTICAL ENANTIOMERS OF MODAFINIL.

Also Published As

Publication number Publication date
CA2556106A1 (en) 2005-08-25
JP2007522147A (en) 2007-08-09
EA009949B1 (en) 2008-04-28
AU2005212229B2 (en) 2011-06-09
EP1718607A4 (en) 2008-05-28
IL176934A0 (en) 2006-12-10
JP4917441B2 (en) 2012-04-18
EP1718607A1 (en) 2006-11-08
AU2005212229A1 (en) 2005-08-25
EA200601390A1 (en) 2006-12-29
WO2005077894A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
IL176934A (en) Use of form v of r-(-)-modafinil in the preparation of a medicament for treating excessive daytime sleepiness and attention deficit hyperactivity disorder (adhd)
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
EP1718602A4 (en) Therapeutic and carrier molecules
AP2008004379A0 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient
IL177482A0 (en) C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
IL180078A (en) 9-cis-retinal derivative for use in the treatment of 11-cis -retinal deficiency
EP1743174A4 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
PL1912650T3 (en) Use of flibanserin in the treatment of obesity
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
IL179121A0 (en) Cycloolefin phosphine ligands and their use in catalysis
HUE050758T2 (en) Glutamate modulating agents in the treatment of mental disorders
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
IL194623A (en) Mazindol combination in the treatment of attention deficit/hyperactivity disorder
EP1768653A4 (en) Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
GB0523576D0 (en) Drug composition and its use in therapy
IL182356A0 (en) Novel cyclic and acyclic propenones and their use in the preparation of medicaments for treating cns disorders
EP1811941A4 (en) Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
GB0422566D0 (en) Improvements in or relating to closure retention and relaese mechanisms
EP1802350A4 (en) Modulation of neuroglia-derived bdnf in the treatment and prevention of pain
GB0522154D0 (en) Novel catalytic materials and their use in the preparation of polymeric materials
TWI370773B (en) Monofilament for use in screen gauze and screen gause using the same
EP1666046A4 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
EP1709962A4 (en) The use of l-butylphthalide in the manufacturing of medicines for the prevention and treatment of cerebral ischemia disease
IL182590A0 (en) Catalyst compositions and their use in the de-enrichment of enantiomerically enriched substrates
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees